Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PDE10A | Q9Y233 | 3/20 | 0.47 |
| ▸ | AAK1 | Q2M2I8 | 2/20 | 0.42 |
| ▸ | HRH4 | Q9H3N8 | 3/20 | 0.39 |
| ▸ | PIK3CD | O00329 | 1/20 | 0.39 |
| ▸ | PIK3R1 | P27986 | 1/20 | 0.37 |
| ▸ | PIK3CA | P42336 | 1/20 | 0.37 |
| ▸ | RET | P07949 | 1/20 | 0.36 |
| ▸ | KIF18A | Q8NI77 | 1/20 | 0.36 |
| ▸ | USP30 | Q70CQ3 | 1/20 | 0.35 |
| ▸ | CHEK2 | O96017 | 1/20 | 0.35 |
| ▸ | KDM4D | Q6B0I6 | 1/20 | 0.35 |
| ▸ | SPR | P35270 | 4/20 | 0.35 |
| ▸ | HRH2 | P25021 | 1/20 | 0.35 |
| ▸ | HRH1 | P35367 | 1/20 | 0.35 |
| ▸ | HRH3 | Q9Y5N1 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4876229 | 0.83 | HRH4 (0.57) | PDE10AAAK1HRH4PIK3CDPIK3R1 | |
| SCHEMBL4875269 | 0.77 | PDE10A (0.46) | PDE10AAAK1HRH4PIK3CDPIK3R1 | |
| SCHEMBL603890 | 0.75 | HRH4 (0.66) | HRH4HRH3 | |
| SCHEMBL23104005 | 0.73 | PDE10A (0.54) | PDE10AAAK1PIK3CDRETKIF18A | |
| SCHEMBL29736507 | 0.73 | PDE10A (0.54) | PDE10AAAK1PIK3CDRETKIF18A | |
| SCHEMBL3816118 | 0.72 | HRH3 (0.57) | PDE10AAAK1HRH4PIK3CDPIK3R1 | |
| SCHEMBL3816114 | 0.72 | HRH3 (0.57) | PDE10AAAK1HRH4PIK3CDPIK3R1 | |
| SCHEMBL604212 | 0.71 | HRH4 (0.62) | HRH4HRH2HRH1HRH3 | |
| SCHEMBL606190 | 0.71 | HRH4 (0.63) | HRH4HRH2HRH1HRH3 | |
| SCHEMBL12604969 | 0.69 | LMNA (0.53) | PDE10AAAK1HRH4PIK3CDKDM4D |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8735411-B2 | Macrocyclic benzofused pyrimidine derivatives | ABBVIE INC. (US) | 2014-05-27 | — | — | US | disclosed |
| US-20080188452-A1 | Macrocyclic Benzofused Pyrimidine Derivatives | ABBVIE INC. | 2008-08-07 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080188452-A1 | Macrocyclic Benzofused Pyrimidine Derivatives | DPYD, TYMS, UMPS | PDE10A 2926/4885AAK1 1956/4885HRH4 3013/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.